Advaxis, Inc. (NASDAQ:ADXS) shares hit a new 52-week low on Thursday . The stock traded as low as $0.39 and last traded at $0.39, with a volume of 4862 shares traded. The stock had previously closed at $0.41.

Several research analysts recently weighed in on ADXS shares. HC Wainwright set a $2.00 price objective on Advaxis and gave the stock a “buy” rating in a research report on Tuesday, November 6th. ValuEngine upgraded Advaxis from a “hold” rating to a “buy” rating in a research report on Thursday, November 1st.

The stock has a market capitalization of $21.79 million, a P/E ratio of -0.17 and a beta of 2.46.

Advaxis (NASDAQ:ADXS) last released its quarterly earnings results on Monday, September 10th. The biotechnology company reported ($0.27) EPS for the quarter, missing the consensus estimate of ($0.25) by ($0.02). Advaxis had a negative return on equity of 165.23% and a negative net margin of 1,062.68%. The firm had revenue of $1.13 million for the quarter, compared to analysts’ expectations of $1.85 million. As a group, research analysts predict that Advaxis, Inc. will post -1.09 earnings per share for the current fiscal year.

In other news, Director Roni Appel purchased 33,333 shares of the stock in a transaction dated Tuesday, September 11th. The stock was acquired at an average cost of $1.20 per share, for a total transaction of $39,999.60. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 7.21% of the company’s stock.

Several institutional investors and hedge funds have recently added to or reduced their stakes in ADXS. Renaissance Technologies LLC boosted its position in shares of Advaxis by 173.0% during the third quarter. Renaissance Technologies LLC now owns 1,191,846 shares of the biotechnology company’s stock worth $1,120,000 after buying an additional 755,352 shares during the period. Paloma Partners Management Co acquired a new stake in shares of Advaxis in the second quarter valued at $265,000. Finally, LMR Partners LLP acquired a new stake in shares of Advaxis in the second quarter valued at $171,000. Institutional investors and hedge funds own 24.81% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Advaxis (ADXS) Sets New 12-Month Low at $0.39” was originally published by Watch List News and is owned by of Watch List News. If you are accessing this story on another website, it was illegally copied and republished in violation of United States and international copyright laws. The correct version of this story can be viewed at

About Advaxis (NASDAQ:ADXS)

Advaxis, Inc, a clinical stage biotechnology company, focuses on the discovery, development, and commercialization of Listeria monocytogenes (Lm) technology based immunotherapies in the United States. It is developing Axalimogene filolisbac and ADXS-Dual that are Lm-LLO immunotherapy product candidates for the treatment of human papilloma virus associated cancers, including cervical, and head and neck cancers.

Further Reading: Asset Allocation, Balancing Your Investments

Receive News & Ratings for Advaxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis and related companies with's FREE daily email newsletter.